Belzupacap sarotalocan is a novel agent that combines tumor-targeting with photoactivation, selectively binding to cancer cells expressing glypican-3 (GPC3) and inducing cell death upon exposure to light from laser use. The gene discussed is GPC3; the disease is cancer.